271 related articles for article (PubMed ID: 33429867)
1. Disrupting Insulin and IGF Receptor Function in Cancer.
Cao J; Yee D
Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33429867
[TBL] [Abstract][Full Text] [Related]
2. Acquired resistance to tamoxifen is associated with loss of the type I insulin-like growth factor receptor: implications for breast cancer treatment.
Fagan DH; Uselman RR; Sachdev D; Yee D
Cancer Res; 2012 Jul; 72(13):3372-80. PubMed ID: 22573715
[TBL] [Abstract][Full Text] [Related]
3. Differential insulin-like growth factor I receptor signaling and function in estrogen receptor (ER)-positive MCF-7 and ER-negative MDA-MB-231 breast cancer cells.
Bartucci M; Morelli C; Mauro L; Andò S; Surmacz E
Cancer Res; 2001 Sep; 61(18):6747-54. PubMed ID: 11559546
[TBL] [Abstract][Full Text] [Related]
4. Role of the insulin-like growth factor system on an estrogen-dependent cancer phenotype in the MCF-7 human breast cancer cell line.
Bradley LM; Gierthy JF; Pentecost BT
J Steroid Biochem Mol Biol; 2008 Mar; 109(1-2):185-96. PubMed ID: 18337089
[TBL] [Abstract][Full Text] [Related]
5. Advances in targeting insulin-like growth factor signaling pathway in cancer treatment.
You L; Liu C; Tang H; Liao Y; Fu S
Curr Pharm Des; 2014; 20(17):2899-911. PubMed ID: 23944362
[TBL] [Abstract][Full Text] [Related]
6. Investigating new therapeutic strategies targeting hyperinsulinemia's mitogenic effects in a female mouse breast cancer model.
Rostoker R; Bitton-Worms K; Caspi A; Shen-Orr Z; LeRoith D
Endocrinology; 2013 May; 154(5):1701-10. PubMed ID: 23515289
[TBL] [Abstract][Full Text] [Related]
7. The insulin-like growth factor-I receptor (IGF-IR) in breast cancer: biology and treatment strategies.
Motallebnezhad M; Aghebati-Maleki L; Jadidi-Niaragh F; Nickho H; Samadi-Kafil H; Shamsasenjan K; Yousefi M
Tumour Biol; 2016 Sep; 37(9):11711-11721. PubMed ID: 27444280
[TBL] [Abstract][Full Text] [Related]
8. The insulin-like growth factor pathway as a target for cancer therapy.
López-Calderero I; Sánchez Chávez E; García-Carbonero R
Clin Transl Oncol; 2010 May; 12(5):326-38. PubMed ID: 20466617
[TBL] [Abstract][Full Text] [Related]
9. Insulin receptor substrates mediate distinct biological responses to insulin-like growth factor receptor activation in breast cancer cells.
Byron SA; Horwitz KB; Richer JK; Lange CA; Zhang X; Yee D
Br J Cancer; 2006 Nov; 95(9):1220-8. PubMed ID: 17043687
[TBL] [Abstract][Full Text] [Related]
10. Targeting insulin-like growth factor in breast cancer therapeutics.
Karamouzis MV; Papavassiliou AG
Crit Rev Oncol Hematol; 2012 Oct; 84(1):8-17. PubMed ID: 22424863
[TBL] [Abstract][Full Text] [Related]
11. Novel human monoclonal antibodies to insulin-like growth factor (IGF)-II that potently inhibit the IGF receptor type I signal transduction function.
Feng Y; Zhu Z; Xiao X; Choudhry V; Barrett JC; Dimitrov DS
Mol Cancer Ther; 2006 Jan; 5(1):114-20. PubMed ID: 16432169
[TBL] [Abstract][Full Text] [Related]
12. Down-regulation of insulin receptor by antibodies against the type I insulin-like growth factor receptor: implications for anti-insulin-like growth factor therapy in breast cancer.
Sachdev D; Singh R; Fujita-Yamaguchi Y; Yee D
Cancer Res; 2006 Feb; 66(4):2391-402. PubMed ID: 16489046
[TBL] [Abstract][Full Text] [Related]
13. Plasma and tissue insulin-like growth factor-I receptor (IGF-IR) as a prognostic marker for prostate cancer and anti-IGF-IR agents as novel therapeutic strategy for refractory cases: a review.
Ozkan EE
Mol Cell Endocrinol; 2011 Sep; 344(1-2):1-24. PubMed ID: 21782884
[TBL] [Abstract][Full Text] [Related]
14. Insulin-like growth factor receptor as a therapeutic target in head and neck cancer.
Barnes CJ; Ohshiro K; Rayala SK; El-Naggar AK; Kumar R
Clin Cancer Res; 2007 Jul; 13(14):4291-9. PubMed ID: 17634559
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic Targeting of the IGF Axis.
Osher E; Macaulay VM
Cells; 2019 Aug; 8(8):. PubMed ID: 31416218
[TBL] [Abstract][Full Text] [Related]
16. Targeting the insulin-like growth factor network in cancer therapy.
Heidegger I; Pircher A; Klocker H; Massoner P
Cancer Biol Ther; 2011 Apr; 11(8):701-7. PubMed ID: 21311212
[TBL] [Abstract][Full Text] [Related]
17. Potential therapeutic strategies to interrupt insulin-like growth factor signaling in breast cancer.
Byron SA; Yee D
Semin Oncol; 2003 Oct; 30(5 Suppl 16):125-32. PubMed ID: 14613033
[TBL] [Abstract][Full Text] [Related]
18. Targeting the insulin-like growth factor axis as a cancer therapy.
Haddad T; Yee D
Future Oncol; 2006 Feb; 2(1):101-10. PubMed ID: 16556077
[TBL] [Abstract][Full Text] [Related]
19. Analysis of signaling pathways related to cell proliferation stimulated by insulin analogs in human mammary epithelial cell lines.
Shukla A; Grisouard J; Ehemann V; Hermani A; Enzmann H; Mayer D
Endocr Relat Cancer; 2009 Jun; 16(2):429-41. PubMed ID: 19153208
[TBL] [Abstract][Full Text] [Related]
20. Antiproliferative and apoptotic effects of a specific anti-insulin-like growth factor I receptor single chain antibody on breast cancer cells.
Motallebnezhad M; Younesi V; Aghebati-Maleki L; Nickho H; Safarzadeh E; Ahmadi M; Movassaghpour AA; Hosseini A; Yousefi M
Tumour Biol; 2016 Nov; 37(11):14841-14850. PubMed ID: 27639384
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
